Abstract
Background/Aim: Afatinib, a 2nd generation epidermal growth factor receptor tyrosine kinase inhibitor (EGFR-TKI) used in treatment of non-small cell l......
小提示:本篇文献需要登录阅读全文,点击跳转登录